文献速递淋巴瘤

美国社区肿瘤实践中伊布替尼治疗套细胞淋巴瘤的模式与结局

Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
PubMed 文献 · Br J Haematol · 2020-10-23

The experience of patients with mantle cell lymphoma (MCL) in community oncology practices, including reasons for treatment discontinuation, is sparse.…

核心结论

  • 社区肿瘤实践中伊布替尼治疗MCL的生存数据与临床试验相似。

主要发现

  • 中位年龄71岁,男性占76%,白人占89%。

临床怎么用

  • 社区实践中伊布替尼治疗MCL的生存结局与临床试验相似,但停药率高,需关注毒性管理。

局限性

  • 回顾性研究设计,数据来源于电子病历数据库,可能存在信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The experience of patients with mantle cell lymphoma (MCL) in community oncology practices, including reasons for treatment discontinuation, is sparse. This retrospective study sought to elucidate treatment patterns and outcomes of patients with MCL treated with ibrutinib in the community setting. Patients were identified from the US Oncology Network electronic medical records database, iKnowMedTM , between 1 November 2013 and 31 October 2016. Descriptive analysis was performed to describe the demographic and clinical characteristics of the population. Kaplan-Meier estimates were performed to determine clinical outcomes. A Cox proportional hazards model was used to identify predictors of survival. Of the 1914 patients identified with MCL, 159 were treated with ibrutinib. The median age was 71 years and the majority were male (76%) and Caucasian (89%). The overall discontinuation rate was 83·6%; the most common reasons were progression (35%) and toxicities (25·6%). The median overall survival and progression-free survival was 25·82 months (95% confidence interval [CI] 19·94, NR) and 19·55 months (95% CI 16·52, 24·28) respectively. In multivariate modelling, patient age was predictive of survival (hazard ratio 1·041, P = 0·0186). Ibrutinib was temporarily reduced in 16·4% (n = 26) and held in 30·2% (n = 48), primarily due to toxicity 66·7% (n = 32). Survival data showed similarities between community oncology practices and clinical trials.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sharman J, Kabadi SM, Clark J, et al. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2020. PMID: 33095453. doi:10.1111/bjh.16922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。